Minneapolis-based Medtronic earned clearance from the Food and Drug Administration for its CardioInsight Noninvasive 3-D Mapping System. While cardiac mapping typically involves clinicians inserting a ...
Sphere-9 demonstrated 73.8% freedom from AFib vs. only 65.8% observed in the control arm. AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people ...
First-of-its-kind, all-in-one HD-mapping and dual energy (pulsed field and radiofrequency) ablation catheter Highly anticipated by electrophysiologists for its innovation and demonstrated safety and ...
Figuring out what is causing an irregular heartbeat typically means an invasive procedure: most often, electrophysiologists insert a catheter to the heart via an artery or vein to get a cardiac “map” ...
On April 26, 2026, Medtronic announced continued momentum for the Affera family of technologies for cardiac arrhythmia ...
Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)Breakthrough device designation granted for use of th ...
Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).
Medtronic is pumping up its activation of heart valve disease patients. The company has partnered with an advocacy group for heart valve disease, Heart-Valve-Surgery.com, to create a digital platform ...
Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results